Entity

Time filter

Source Type

Brooklyn, NY, United States

Trademark
Endocrine Technology and Endocrine Transplant Inc. | Date: 2003-10-07

Pharmaceutical preparations for the treatment of hyperkalemia, which lowers serum potassium levels, and stimulates the immune system.


Trademark
Endocrine Technology | Date: 2006-12-26

Animal feed supplements; feed supplements for horses and livestock.


News Article | September 16, 2014
Site: businesswireindia.com

Endocrine Technology, L.L.C. is a New York-based biotechnology company detailed at www.etbondusa.com. Kumar Shah, M.D., President of the company, brings the most advanced technology to solve the ebola crisis. There is an enormous humanitarian and scientific need for the masses to get united to fight the ebola crisis. There is a growing scientific consensus that: a. An expedient solution to the crisis must be found in an available drug. b. Evidence-based scientific data should be unearthed that is deeply buried in medical literature. c. The potential solution must be in keeping with cutting edge advances in genomics and fundamentals of immunology. “It is expected that meeting the above criteria will give confidence and galvanize global cooperation to advance such technology to save lives expediently. The mortality rate may surge to 1.2 million in the coming year,” Dr. Kumar Shah stated. Endocrine Technology, LLC and its dedicated “ETBOND Team members” have advanced such a technology. www.etbondusa.com provides links to patent application, references, interim drug draft label and slide presentations. The patent application details a novel immune modulation drug. During therapy it down regulates inflammatory and bleeding responses seen in ebola infected patients by inhibiting serine proteases. During the recovery phase the drug stimulates host immune responses to kill ebola. The later strategy can be extended to asymptomatic patients to cure ebola infection. The modeling of three-dimensional interaction of ebola with host and its immune system suggest that ebola is a highly charged particle that activates proteases and can be effectively neutralized by ET 007, a drug that is a nano formulated version of a globally available drug. It is safe and effective to initiate global efforts to treat and eradicate the ebola crisis. Kumar Shah, M.D. is the USA trained Board Certified Physician, President and Patent developer. He has 20 plus years of medical and biotechnology industry experience. He is in charge of global Medical and Technology Consulting services for ebola. He is assisted by a dedicated ETBOND Team.


Hobbs T.R.,Oregon National Primate Research Center | Blue S.W.,Endocrine Technology | Park B.S.,Oregon Health And Science University | Greisel J.J.,Oregon National Primate Research Center | And 2 more authors.
Journal of the American Association for Laboratory Animal Science | Year: 2015

Most biomedical facilities that use rhesus macaques (Macaca mulatta) limit the amount of blood that may be collected for experimental purposes. These limits typically are expressed as a percentage of blood volume (BV), estimated by using a fixed ratio of blood (mL) per body weight (kg). BV estimation ratios vary widely among facilities and typically do not factor in variables known to influence BV in humans: sex, age, and body condition. We used indicator dilution methodology to determine the BV of 20 adult rhesus macaques (10 male, 10 female) that varied widely in body condition. We measured body composition by using dual-energy X-ray absorptiometry, weight, crown-to-rump length, and body condition score. Two indicators, FITC-labeled hydroxyethyl starch (FITC-HES) and radioiodinated rhesus serum albumin (125I-RhSA), were injected simultaneously, followed by serial blood collection. Plasma volume at time 0 was determined by linear regression. BV was calculated from the plasma volume and Hct. We found that BV calculated by using FITC-HES was consistently lower than BV calculated by using 125I-RhSA. Sex and age did not significantly affect BV. Percentage body fat was significantly associated with BV. Subjects categorized as having 'optimal' body condition score had 18% body fat and 62.1 mL/kg BV (by FITC-HES; 74.5 mL/kg by 125I-RhSA). Each 1% increase in body fat corresponded to approximately 1 mL/kg decrease in BV. Body condition score correlated with the body fat percentage (R2 = 0.7469). We provide an equation for calculating BV from weight and body condition score. Source


Discover hidden collaborations